Loading patent…
AssigneeZoltan Kiss Consulting
InventorZoltan Kiss
Estimating the term…
This invention provides an alkaline phosphatase or an active derivative of placental alkaline phosphatase to prevent or reduce one, two, or all three of interrelated metabolic disorders, i.e. insulin resistance, hyperinsulinemia, and dyslipidemia. Alkaline phosphatase or an active derivative of placental alkaline phosphatase is suitable to prevent or reduce diseases and disorders relating to insulin resistance, hyperinsulinemia, and dyslipidemia including type 2 diabetes, epithelial cancers, myopia, acne, acanthosis nigricans, polycystic ovary syndrome, cutaneous papillomas, hypertension, renal dysfunction, microvascular and macrovascular diseases, atherosclerosis, nonalcoholic fat liver, dyslipidemia, sleep-disordered breathing, atherosclerosis, coronary artery (heart) disease, cardiovascular disease, heart failure, accelerated aging, stroke, and neurological diseases such as Alzheimer.
A method of preventing or reducing one or more interrelated metabolic disorders selected from the group consisting essentially of dyslipidemia, insulin resistance, and hyperinsulinemia, comprising the step of administering a therapeutically effective amount of an alkaline phosphatase preparation to prevent or reduce the one or more metabolic disorders and as a consequence prevent or reduce development of related diseases and disorders in a human or another mammal.
A therapeutically effective amount of an alkaline phosphatase preparation for the treatment of metabolic disorders selected from a group consisting essentially of dyslipidemia, insulin resistance, and hyperinsulinemia.
Dependencies are inferred from the claim text.